{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:56:54Z","timestamp":1787237814049,"version":"build-2736575974"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-programmed death-1 (PD-1)\/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China that has received approvals from the National Medical Products Administration to treat classical Hodgkin\u2019s lymphoma, hepatocellular carcinoma, and squamous and non-squamous NSCLC. In a prospective clinical study we led, neoadjuvant sintilimab has led to major and complete pathologic responses, which are recommended as surrogate endpoints for neoadjuvant immunotherapy; however, its effect remains inconclusive in pulmonary ground glass nodules. Meanwhile, combination plans seem more likely to be satisfying therapeutic options. Specifically, sintilimab plus platinum-based chemotherapy plans conferred better anti-tumor efficacy and clinical benefits compared to chemotherapy alone, which led to their approval in China and the acceptance of a biological license application in the US. Besides, the combination with other plans, such as docetaxel, cytokine-induced killer cell immunotherapy, radiation therapy, and anlotinib have also shown promising anti-tumor efficacy, with acceptable toxicities, and are therefore worth further exploration. In addition, several clinical trials on NSCLC at our center are ongoing. In general, sintilimab and its combinatorial plans were effective and well tolerated, but the treatment requires appropriate timing; pathologic responses can be surrogate endpoints for neoadjuvant immunotherapy, while more effective biomarkers are warranted. This study provides an overview of sintilimab-based clinical trials on NSCLC, and may support further investigation of sintilimab in future clinical trials.<\/jats:p>","DOI":"10.1186\/s40364-022-00363-7","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T06:12:05Z","timestamp":1650262325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Sintilimab for the treatment of non-small cell lung cancer"],"prefix":"10.1186","volume":"10","author":[{"given":"Lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"issue":"3","key":"363_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"363_CR2","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jtho.2016.05.024","volume":"11","author":"MA Socinski","year":"2016","unstructured":"Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, et al. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016;11(9):1411\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2016.05.024.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"363_CR3","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1378\/chest.123.6.2096","volume":"123","author":"D Datta","year":"2003","unstructured":"Datta D, Lahiri B. Preoperative Evaluation of Patients Undergoing Lung Resection Surgery. Chest. 2003;123(6):2096\u2013103. https:\/\/doi.org\/10.1378\/chest.123.6.2096.","journal-title":"Chest"},{"issue":"9928","key":"363_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(13)62159-5.","journal-title":"Lancet"},{"issue":"9722","key":"363_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","volume":"375","author":"R Arriagada","year":"2010","unstructured":"Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(10)60059-1.","journal-title":"Lancet"},{"issue":"1","key":"363_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/ajco.12608","volume":"13","author":"Y Shi","year":"2017","unstructured":"Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, et al. China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version). Asia Pac J Clin Oncol. 2017;13(1):87\u2013103. https:\/\/doi.org\/10.1111\/ajco.12608.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"363_CR7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014.","journal-title":"Immunity"},{"issue":"8","key":"363_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660\u20139. https:\/\/doi.org\/10.1038\/s41422-020-0343-4.","journal-title":"Cell Res"},{"issue":"6382","key":"363_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"issue":"3","key":"363_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM. Sintilimab: First Global Approval. Drugs. 2019;79(3):341\u20136. https:\/\/doi.org\/10.1007\/s40265-019-1066-z.","journal-title":"Drugs"},{"key":"363_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594558","volume":"10","author":"L Zhang","year":"2020","unstructured":"Zhang L, Mai W, Jiang W, Geng Q. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020;10: 594558. https:\/\/doi.org\/10.3389\/fonc.2020.594558.","journal-title":"Front Oncol"},{"key":"363_CR12","unstructured":"National Medical Products Administration. (2021). Drug Approval Documents Released on June 3, 2021. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20210603160927171.html [Accessed 22 Feb\u00a02022]."},{"key":"363_CR13","unstructured":"National Medical Products Administration. (2021). Drug Approval Documents Released on June 25, 2021. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20210625204754172.html [Accessed 22 Feb\u00a02022]."},{"key":"363_CR14","unstructured":"National Medical Products Administration. (2021). Drug Approval Documents Released on February 2, 2021. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20210202223610138.html [Accessed 22 Feb\u00a02022]."},{"issue":"5","key":"363_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","volume":"15","author":"S Gao","year":"2020","unstructured":"Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816\u201326. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.017.","journal-title":"J Thorac Oncol"},{"issue":"(15_suppl)","key":"363_CR16","doi-asserted-by":"publisher","first-page":"8522","DOI":"10.1200\/JCO.2021.39.15_suppl.8522","volume":"39","author":"S Gao","year":"2021","unstructured":"Gao S, Li N, Gao S, Xue Q, Wang S, Lv F, et al. Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC. J Clin Oncol. 2021;39(15_suppl):8522. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8522.","journal-title":"J Clin Oncol"},{"issue":"10","key":"363_CR17","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Y Yang","year":"2020","unstructured":"Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020;15(10):1636\u201346. https:\/\/doi.org\/10.1016\/j.jtho.2020.07.014.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"363_CR18","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501\u201311. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.011.","journal-title":"J Thorac Oncol"},{"key":"363_CR19","unstructured":"National Comprehensive Cancer Network. (2021). NCCN Guidelines, Non-Small Cell Lung Cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450 [Accessed 22 Feb\u00a02022]."},{"issue":"5.5","key":"363_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.6004\/jnccn.2019.5005","volume":"17","author":"MA Gubens","year":"2019","unstructured":"Gubens MA, Davies M. NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2019;17(5.5):574\u20138. https:\/\/doi.org\/10.6004\/jnccn.2019.5005.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"363_CR21","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","volume":"17","author":"DS, Ettinger","year":"2019","unstructured":"Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464\u201372. https:\/\/doi.org\/10.6004\/jnccn.2019.0059.","journal-title":"J Natl Compr Canc Netw"},{"key":"363_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174404","volume":"909","author":"M Sanaei","year":"2021","unstructured":"Sanaei M, Pourbagheri-Sigaroodi A, Kaveh V, Abolghasemi H, Ghaffari SH, Momeny M, et al. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. Eur J Pharmacol. 2021;909: 174404. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174404.","journal-title":"Eur J Pharmacol"},{"key":"363_CR23","doi-asserted-by":"publisher","first-page":"175883592110298","DOI":"10.1177\/17588359211029826","volume":"13","author":"J Gan","year":"2021","unstructured":"Gan J, Huang Y, Fang W, Zhang L. Research progress in immune checkpoint inhibitors for lung cancer in China. Ther Adv Med Oncol. 2021;13:17588359211029826. https:\/\/doi.org\/10.1177\/17588359211029826.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"363_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/abt\/tby005","volume":"1","author":"S Zhang","year":"2018","unstructured":"Zhang S, Zhang M, Wu W, Yuan Z, Tsun A, Wu M, et al. Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antib Ther. 2018;1(2):65\u201373. https:\/\/doi.org\/10.1093\/abt\/tby005.","journal-title":"Antib Ther"},{"issue":"5","key":"363_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/abbs\/gmab020","volume":"53","author":"M Ma","year":"2021","unstructured":"Ma M, Qi H, Hu C, Xu Z, Wu F, Wang N, et al. The binding epitope of sintilimab on PD-1 revealed by AbMap. Acta Biochim Biophys Sin (Shanghai). 2021;53(5):628\u201335. https:\/\/doi.org\/10.1093\/abbs\/gmab020.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"8","key":"363_CR26","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","volume":"11","author":"J Wang","year":"2019","unstructured":"Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019;11(8):1443\u201351. https:\/\/doi.org\/10.1080\/19420862.2019.1654303.","journal-title":"MAbs"},{"issue":"1","key":"363_CR27","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12\u20139. https:\/\/doi.org\/10.1016\/S2352-3026(18)30192-3.","journal-title":"Lancet Haematol"},{"issue":"15_suppl","key":"363_CR28","doi-asserted-by":"publisher","first-page":"e15125","DOI":"10.1200\/JCO.2018.36.15_suppl.e15125","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J, Jia R, Wang Y, Liu R, Zhao C, Zhou H, et al. A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors. J Clin Oncol. 2018;36(15_suppl):e15125. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e15125.","journal-title":"J Clin Oncol"},{"issue":"2","key":"363_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2214\/ajr.169.2.9242736","volume":"169","author":"J Collins","year":"1997","unstructured":"Collins J, Stern EJ. Ground-glass opacity at CT: the ABCs. AJR Am J Roentgenol. 1997;169(2):355\u201367. https:\/\/doi.org\/10.2214\/ajr.169.2.9242736.","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"363_CR30","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.21037\/tlcr-21-561","volume":"10","author":"J Chen","year":"2021","unstructured":"Chen J, Xie F, Zheng X, Li Y, Liu S, Ma KC, et al. Mobile 3-dimensional (3D) C-arm system-assisted transbronchial biopsy and ablation for ground-glass opacity pulmonary nodules: a case report. Transl Lung Cancer Res. 2021;10(7):3312\u20139. https:\/\/doi.org\/10.21037\/tlcr-21-561.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"363_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21037\/atm.2017.07.28","volume":"6","author":"M Migliore","year":"2018","unstructured":"Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, et al. Ground glass opacities management in the lung cancer screening era. Ann Transl Med. 2018;6(5):90. https:\/\/doi.org\/10.21037\/atm.2017.07.28.","journal-title":"Ann Transl Med"},{"issue":"5 Suppl","key":"363_CR32","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.12-2359","volume":"143","author":"JA Howington","year":"2013","unstructured":"Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-e313S. https:\/\/doi.org\/10.1378\/chest.12-2359.","journal-title":"Chest"},{"issue":"(suppl_4)","key":"363_CR33","first-page":"S735","volume":"31","author":"R Yin","year":"2020","unstructured":"Yin R, Xu L, Xia W. 1232P - An exploratory study of a PD-1 inhibitor for high-risk multiple ground-glass nodules (mGGNs) in synchronous stage I non-small cell lung cancer patients. Ann Oncol. 2020;31(suppl_4):S735-43.","journal-title":"Ann Oncol"},{"issue":"(15_suppl)","key":"363_CR34","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1200\/JCO.2021.39.15_suppl.8545","volume":"39","author":"B Cheng","year":"2021","unstructured":"Cheng B, Li C, Zhao Y, He J. The efficacy of PD-1 antibody sintilimab on ground glass opacity lesions in patients with early-stage multiple primary lung cancer (CCTC-1901, NCT04026841). J Clin Oncol. 2021;39(15_suppl):8545. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8545.","journal-title":"J Clin Oncol"},{"issue":"(11)","key":"363_CR35","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1002\/ijc.32366","volume":"145","author":"H Liang","year":"2019","unstructured":"Liang H, Liu Z, Cai X, Pan Z, Chen D, Li C, et al. PD\u2010(L)1 inhibitors vs. chemotherapy vs. their combination in front\u2010line treatment for NSCLC: An indirect comparison. Int J Cancer. 2019;145(11):3011\u201321. https:\/\/doi.org\/10.1002\/ijc.32366.","journal-title":"Int J Cancer"},{"issue":"3","key":"363_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00262-020-02738-x","volume":"70","author":"H Jiang","year":"2021","unstructured":"Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, et al. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunol Immunother. 2021;70(3):857\u201368. https:\/\/doi.org\/10.1007\/s00262-020-02738-x.","journal-title":"Cancer Immunol Immunother"},{"key":"363_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.015","author":"Y Yang","year":"2021","unstructured":"Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, et al. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncol. 2021. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.015.","journal-title":"J Thorac Oncol"},{"key":"363_CR38","unstructured":"Innovent. (2021). The U.S. FDA has accepted the market listing application of sintilimab in combination with pemetrexed and platinum for the treatment of non-squamous non-small cell lung cancer as a first-line therapy. http:\/\/cn.innoventbio.com\/#\/news\/259 [Accessed 22 Feb\u00a02022]."},{"key":"363_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03903-0","author":"X Lin","year":"2022","unstructured":"Lin X, Deng H, Li S, Xie X, Chen C, Cai L, et al. Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study. J Cancer Res Clin Oncol. 2022. https:\/\/doi.org\/10.1007\/s00432-021-03903-0.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"suppl_7","key":"363_CR40","doi-asserted-by":"publisher","first-page":"S1428","DOI":"10.1016\/annonc\/annonc787","volume":"32","author":"C Zhou","year":"2021","unstructured":"Zhou C, Gao G, Wu L, Wang Z, Chen G, Huang D, et al. Subgroup analysis of ORIENT-12: Efficacy of sintilimab in combination with gemcitabine and platinum- based chemotherapy in patients with advanced or metastatic squamous non-small cell lung cancer. Ann Oncol. 2021;32(suppl_7):S1428-57. https:\/\/doi.org\/10.1016\/annonc\/annonc787.","journal-title":"Ann Oncol"},{"key":"363_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2022.01.039","author":"P Zhang","year":"2022","unstructured":"Zhang P, Dai J, Sun F, Xia H, He W, Duan L, et al. Neoadjuvant Sintilimab and Chemotherapy for Resectable Stage IIIA Non-small-cell Lung Cancer. Ann Thorac Surg. 2022. https:\/\/doi.org\/10.1016\/j.athoracsur.2022.01.039.","journal-title":"Ann Thorac Surg"},{"issue":"suppl_6","key":"363_CR42","doi-asserted-by":"publisher","first-page":"S1386","DOI":"10.1016\/annonc\/annonc367","volume":"31","author":"Z Wang","year":"2020","unstructured":"Wang Z, Han X, Guo J, Zhu D, Zhang X, Tang X. 402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2020;31(suppl_6):S1386-406. https:\/\/doi.org\/10.1016\/annonc\/annonc367.","journal-title":"Ann Oncol"},{"issue":"suppl_7","key":"363_CR43","doi-asserted-by":"publisher","first-page":"S1373","DOI":"10.1016\/annonc\/annonc784","volume":"32","author":"Z Wang","year":"2021","unstructured":"Wang Z, Han X, Guo J, Tang X, Zhu C, Zhu H, et al. 14P - Circulating tumor DNA (ctDNA) residual and dynamics of ctDNA clonality indicated therapeutic efficacy of Sintilimab plus Docetaxel in previously treated advanced non-small cell lung cancer. Ann Oncol. 2021;32(suppl_7):S1373-91. https:\/\/doi.org\/10.1016\/annonc\/annonc784.","journal-title":"Ann Oncol"},{"key":"363_CR44","unstructured":"ClinicalTrials.gov. (2021). Homepage. https:\/\/clinicaltrials.gov [Accessed 22 Feb\u00a02022]."},{"issue":"1","key":"363_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jcp.28977","volume":"235","author":"M Mohsenzadegan","year":"2020","unstructured":"Mohsenzadegan M, Peng RW, Roudi R. Dendritic cell\/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. J Cell Physiol. 2020;235(1):74\u201386. https:\/\/doi.org\/10.1002\/jcp.28977.","journal-title":"J Cell Physiol"},{"key":"363_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101437","volume":"49","author":"E Leon","year":"2020","unstructured":"Leon E, Ranganathan R, Savoldo B. Adoptive T cell therapy: Boosting the immune system to fight cancer. Semin Immunol. 2020;49: 101437. https:\/\/doi.org\/10.1016\/j.smim.2020.101437.","journal-title":"Semin Immunol"},{"issue":"11","key":"363_CR47","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00262-012-1260-2","volume":"61","author":"R Li","year":"2012","unstructured":"Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012;61(11):2125\u201333. https:\/\/doi.org\/10.1007\/s00262-012-1260-2.","journal-title":"Cancer Immunol Immunother"},{"key":"363_CR48","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/annonc\/annonc367","volume":"15","author":"X Ren","year":"2021","unstructured":"Ren X, Zhou L. A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)-CCICC-002. J Clin Oncol. 2021;15:2531. https:\/\/doi.org\/10.1016\/annonc\/annonc367.","journal-title":"J Clin Oncol"},{"issue":"2","key":"363_CR49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/annonc\/mdx790","volume":"29","author":"T Kordbacheh","year":"2018","unstructured":"Kordbacheh T, Honeychurch J, Blackhall F, Faivre-Finn C, Illidge T. Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms. Ann Oncol. 2018;29(2):301\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdx790.","journal-title":"Ann Oncol"},{"issue":"8","key":"363_CR50","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","volume":"13","author":"MB Bernstein","year":"2016","unstructured":"Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516\u201324. https:\/\/doi.org\/10.1038\/nrclinonc.2016.30.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"363_CR51","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.jtho.2021.04.002","volume":"16","author":"N Andruska","year":"2021","unstructured":"Andruska N, Stowe HB, Crockett C, Liu W, Palma D, Faivre-Finn C, et al. Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios. J Thorac Oncol. 2021;16(7):1075\u201385. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.002.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"363_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijrobp.2020.05.002","volume":"108","author":"L Yin","year":"2020","unstructured":"Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, et al. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020;108(1):212\u201324. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.05.002.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"363_CR53","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.ijrobp.2020.07.2215","volume":"108S","author":"R Li","year":"2020","unstructured":"Li R, Chen L, Zhang Y, Mei LY, Zhou L, Zhu X, et al. Safety and Tolerability Evaluation of Sintilimab in Combination with Low Dose Radiation and SBRT in Treatment Naive Stage IV PD-L1 Positive NSCLC Patients. Int J Radiat Oncol Biol Phys. 2020;108S(3):S72\u20133.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"363_CR54","unstructured":"ClinicalTrials.gov. (2021). Search results. https:\/\/clinicaltrials.gov\/ct2\/results?cond=lung+cancer&term=sintilimab+radiotherapy&cntry=&state=&city=&dist= [Accessed 22 Feb\u00a02022]."},{"issue":"6","key":"363_CR55","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.176.6.1693","volume":"176","author":"K Inaba","year":"1992","unstructured":"Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte\/macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693\u2013702. https:\/\/doi.org\/10.1084\/jem.176.6.1693.","journal-title":"J Exp Med"},{"key":"363_CR56","unstructured":"ClinicalTrials.gov. (2021). NCT04106180. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04106180?term=NCT04106180&draw=2&rank=1 [Accessed February 22, 2022]."},{"issue":"1","key":"363_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13014-021-01905-3","volume":"16","author":"J Ni","year":"2021","unstructured":"Ni J, Zhou Y, Wu L, Ai X, Dong X, Chu Q, et al. Sintilimab, stereotactic body radiotherapy and granulocyte\u2013macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiat Oncol. 2021;16(1):177. https:\/\/doi.org\/10.1186\/s13014-021-01905-3.","journal-title":"Radiat Oncol"},{"issue":"1","key":"363_CR58","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"363_CR59","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/bjc.2017.478","volume":"118","author":"B Han","year":"2018","unstructured":"Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654\u201361. https:\/\/doi.org\/10.1038\/bjc.2017.478.","journal-title":"Br J Cancer"},{"issue":"11","key":"363_CR60","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. Jama Oncol. 2018;4(11):1569\u201375. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039.","journal-title":"Jama Oncol"},{"issue":"4","key":"363_CR61","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","volume":"16","author":"T Chu","year":"2021","unstructured":"Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, et al. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. J Thorac Oncol. 2021;16(4):643\u201352. https:\/\/doi.org\/10.1016\/j.jtho.2020.11.026.","journal-title":"J Thorac Oncol"},{"key":"363_CR62","unstructured":"Chinese Clinical Trial Registry. (2019). ChiCTR1900025651. https:\/\/www.chictr.org.cn\/showproj.aspx?proj=40288 [Accessed 22 Feb\u00a02022]."},{"key":"363_CR63","unstructured":"Chinese Clinical Trial Registry. (2019). ChiCTR1900023074. https:\/\/www.chictr.org.cn\/showproj.aspx?proj=38877 [Accessed 22 Feb\u00a02022]."},{"key":"363_CR64","unstructured":"Chinese Clinical Trial Registry. (2020). ChiCTR2000034888. https:\/\/www.chictr.org.cn\/showproj.aspx?proj=56928 [Accessed 22 Feb\u00a02022]."},{"issue":"21","key":"363_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019790","volume":"99","author":"L Zhang","year":"2020","unstructured":"Zhang L, Mai W, Hao B, Jiang W, Geng Q. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report. Medicine (Baltimore). 2020;99(21): e19790. https:\/\/doi.org\/10.1097\/MD.0000000000019790.","journal-title":"Medicine (Baltimore)"},{"key":"363_CR66","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.1126\/science.aax0182","volume":"367","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:6477. https:\/\/doi.org\/10.1126\/science.aax0182.","journal-title":"Science"},{"issue":"7","key":"363_CR67","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.21037\/tlcr-21-259","volume":"10","author":"S Ren","year":"2021","unstructured":"Ren S, Xu A, Lin Y, Camidge DR, Di Maio M, Califano R, et al. A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future. Transl Lung Cancer Res. 2021;10(7):3264\u201375. https:\/\/doi.org\/10.21037\/tlcr-21-259.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"363_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100244","volume":"6","author":"EB Ulas","year":"2021","unstructured":"Ulas EB, Dickhoff C, Schneiders FL, Senan S, Bahce I. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open. 2021;6(5): 100244. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100244.","journal-title":"ESMO Open"},{"issue":"4","key":"363_CR69","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11523-021-00818-1","volume":"16","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Gao Y, Xue Q, Gao S, He J. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Targ Oncol. 2021;16(4):425\u201334. https:\/\/doi.org\/10.1007\/s11523-021-00818-1.","journal-title":"Targ Oncol"},{"issue":"21","key":"363_CR70","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976\u201386. https:\/\/doi.org\/10.1056\/NEJMoa1716078.","journal-title":"N Engl J Med"},{"issue":"1","key":"363_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41698-020-00135-2","volume":"4","author":"Y Ling","year":"2020","unstructured":"Ling Y, Li N, Li L, Guo C, Wei J, Yuan P, et al. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. NPJ Precis Oncol. 2020;4(1):32. https:\/\/doi.org\/10.1038\/s41698-020-00135-2.","journal-title":"NPJ Precis Oncol"},{"key":"363_CR72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctrv.2019.03.004","volume":"75","author":"C Proto","year":"2019","unstructured":"Proto C, Ferrara R, Signorelli D, Lo Russo G, Galli G, Imbimbo M, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019;75:39\u201351. https:\/\/doi.org\/10.1016\/j.ctrv.2019.03.004.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"363_CR73","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41698-021-00244-6","volume":"6","author":"S Wang","year":"2022","unstructured":"Wang S, Yuan P, Mao B, Li N, Ying J, Tao X, et al. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ Precis Oncol. 2022;6(1):2. https:\/\/doi.org\/10.1038\/s41698-021-00244-6.","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"363_CR74","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","volume":"47","author":"X Tao","year":"2020","unstructured":"Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1209\u201319. https:\/\/doi.org\/10.1007\/s00259-020-04711-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"363_CR75","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/JTO.0000000000000526","volume":"10","author":"KM Kerr","year":"2015","unstructured":"Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol. 2015;10(7):985\u20139. https:\/\/doi.org\/10.1097\/JTO.0000000000000526.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"363_CR76","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdv489","volume":"27","author":"M Ilie","year":"2016","unstructured":"Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdv489.","journal-title":"Ann Oncol"},{"issue":"22","key":"363_CR77","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(22):2109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1616288.","journal-title":"N Engl J Med"},{"issue":"10","key":"363_CR78","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, et al. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016;27(10):1953\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw289.","journal-title":"Ann Oncol"},{"key":"363_CR79","doi-asserted-by":"publisher","first-page":"20090","DOI":"10.1038\/srep20090","volume":"6","author":"J Sheng","year":"2016","unstructured":"Sheng J, Fang W, Yu J, Chen N, Zhan J, Ma Y, et al. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep. 2016;6:20090. https:\/\/doi.org\/10.1038\/srep20090.","journal-title":"Sci Rep"},{"key":"363_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102084","volume":"89","author":"MG McNamara","year":"2020","unstructured":"McNamara MG, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treat Rev. 2020;89: 102084. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102084.","journal-title":"Cancer Treat Rev"},{"issue":"6230","key":"363_CR81","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Sci. 2015;348(6230):124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Sci"},{"issue":"9","key":"363_CR82","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0134-3.","journal-title":"Nat Med"},{"issue":"17","key":"363_CR83","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/cancers13174280","volume":"13","author":"B Honrubia-Peris","year":"2021","unstructured":"Honrubia-Peris B, Garde-Noguera J, Garc\u00eda-S\u00e1nchez J, Piera-Molons N, Llombart-Cussac A, Fern\u00e1ndez-Murga ML. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers. 2021;13(17):4280. https:\/\/doi.org\/10.3390\/cancers13174280.","journal-title":"Cancers"},{"issue":"2","key":"363_CR84","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020;183(2):363\u201376. https:\/\/doi.org\/10.1016\/j.cell.2020.09.001.","journal-title":"Cell"},{"issue":"1","key":"363_CR85","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):39. https:\/\/doi.org\/10.1038\/s41572-020-0160-6.","journal-title":"Nat Rev Dis Primers"},{"key":"363_CR86","unstructured":"National Institutes of Health. (2019). Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm [Accessed 22 Feb\u00a02022]."},{"key":"363_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen Y, Du X, Liu J, Huang C, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363: k4226. https:\/\/doi.org\/10.1136\/bmj.k4226.","journal-title":"BMJ"},{"issue":"12","key":"363_CR88","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. Jama Oncol. 2018;4(12):1721. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923.","journal-title":"Jama Oncol"},{"issue":"9","key":"363_CR89","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/S1470-2045(21)00333-8","volume":"22","author":"X Zhou","year":"2021","unstructured":"Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021;22(9):1265\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(21)00333-8.","journal-title":"Lancet Oncol"},{"issue":"5","key":"363_CR90","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/cncr.33270","volume":"127","author":"M Wang","year":"2021","unstructured":"Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, et al. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non\u2013small cell lung cancer: A meta-analysis of randomized control trials. Cancer. 2021;127(5):777\u201386. https:\/\/doi.org\/10.1002\/cncr.33270.","journal-title":"Cancer"},{"issue":"1","key":"363_CR91","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2018","unstructured":"Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71\u201383. https:\/\/doi.org\/10.1093\/annonc\/mdx686.","journal-title":"Ann Oncol"},{"issue":"10","key":"363_CR92","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jtho.2020.08.013","volume":"15","author":"VK Lam","year":"2020","unstructured":"Lam VK, Forde PM. Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer. J Thorac Oncol. 2020;15(10):1556\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.013.","journal-title":"J Thorac Oncol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-022-00363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-022-00363-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-022-00363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:04:47Z","timestamp":1650351887000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-022-00363-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1186\/s40364-022-00363-7","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,18]]},"assertion":[{"value":"9 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}